Protection provided by cyclosporin a against excitotoxic neuronal death is genotype dependent

Epilepsia

Volumn 44, Issue 8, 2003, Pages 995-1002

  Santos, Julia Belen ^a   Schauwecker, Paula Elyse ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Excitotoxicity; Kainate; Mitochondria; Mouse strain; Resistance; Seizures

Indexed keywords

CYCLOSPORIN A; KAINIC ACID; N METHYL DEXTRO ASPARTIC ACID; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CELL LOSS; CELL PROTECTION; CONTROLLED STUDY; DRUG MECHANISM; GENOTYPE; HIPPOCAMPUS; ISCHEMIA; MALE; MICROSCOPY; MITOCHONDRION; MOUSE; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; SEIZURE;

ANIMALS; CELL DEATH; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; EPILEPSY; GENOTYPE; HIPPOCAMPUS; ION CHANNELS; KAINIC ACID; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; PHENOTYPE; PREMEDICATION; TACROLIMUS;

EID: 0043073123     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2003.66302.x     Document Type: Article

References (67)

1. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623-34.
2. Choi DW. Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci 1988;11:465-9.
3. Olney JW. Inciting excitotoxic cytocide among central neurons. In: Schwarcz R, Ben-Ari Y, eds. Advances in experimental medicine and biology. New York: Plenum Press, 1986:632-45.
4. Olney JW. Excitatory amino acids and neuropsychiatric diseases. Biol Psychiatry 1989;26:505-25.
5. Choi DW. Ischemia-induced neuronal apoptosis. Curr Opin Neurobiol 1996;6:667-72.
6. Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 1999;81:163-221.
7. Lipton SA, Rosenberg PA. Excitatory amino acids rise to toxic levels upon impact injury to the rat spinal cord. Brain Res 1994;547:344-8.
8. Mattson MP, Mark RJ. Excitotoxicity and excitoprotection in vitro. In: Siesjö BK, Wieloch T, eds. Advances in neurology: cellular and molecular mechanisms of ischemic brain damage. Philadelphia: Lippincott-Raven, 1996:1-35.
9. Choi DW. Bench to bedside: the glutamate connection. Science 1992;258:241-3.
10. Rothman SM. Excitotoxins: possible mechanisms of action. Ann N Y Acad Sci 1992;648:133-9.
11. 2+homeostasis. J Neurochem 1996;66:403-11.
12. Budd SL. Nicholls DG. Mitochondria, calcium regulation, and acute glutamate excitotoxicity in cultured cerebellar granule cells. J Neurochem 1996;67:2282-91.
13. Stout AK, Raphael HM, Kanterewicz BI, et al. Glutamate-induced neuron death requires mitochondrial calcium uptake. Nat Neurosci 1998:1:366-73.
14. 2+ loads by mitochondria in cultured rat hippocampal neurons, J Neurophysiol 1996;76:1611-21.
15. - induced calcium loads in cultured cortical neurons. J Neurosci 1995;15:1318-28.
16. 2+ following intense glutamate stimulation of cultured rat forebrain neurons. J Physiol 1997;498:31-47.
17. 2+-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress. Biochem J 1988;255:357-60.
18. Halestrap AP, Kerr PM, Javadov S, et al, Elucidating the molecular mechanism of the permeability transition pore and its role in reperfusion injury of the heart. Biochim Biophys Acta 1998;1366:79-94.
19. Nicholls DG, Budd SL. Mitochondria and neuronal survival. Physiol Rev 2000;80:315-60.
20. Packer MA, Murphy MP. Peroxynitrite formed by simultaneous nitric oxide and superoxide generation causes cyclosporine-A-sensitive mitochondrial calcium efflux and depolarization. Eur J Riochem 1995;234:231-9.
21. Matsumoto S, Friberg H, Drake M, et al. Blockade of the mitochondrial permeability transition pore diminishes infarct size in the rat after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab 1999;19:736-41.
22. Uchino H, Elmer E, Uchino K, et al. Cyclosporine A dramatically ameliorates CA1 hippocampal damage following transient forebrain ischaemia in the rat. Acta Physiol Scand 1995;155:469-71.
23. Uchino H, Elmer E, Uchino K, et al. Amelioration by cyclosporine A of brain damage in transient forebrain ischemia in the rat. Brain Res 1998;812:216-26.
24. Yoshimoto T, Siesjö BK. Posttreatment with the immunosuppressant cyclosporine A in transient focal ischemia. Brain Res 1999;839:283-91.
25. Okonkwo DO, Povlishock JT. An intrathecal bolus of cyclosporine A before injury preserved mitochondrial permeability transition pore to cyclosporine A and ADP. Arch Biochem Biophys 1999;311:219-28.
26. Okonkwo DO, Buki A, Siman R, et al. Cyclosporine A limits calcium-induced axonal damage following traumatic brain injury. Neuroreport 1999;10:353-8.
27. Scheff SW, Sullivan PG. Cyclosporine A significantly ameliorates cortical damage following experimental traumatic brain injury in rodents. J Neurotrauma 1999;16:783-92.
28. Schinder AF, Olson EC, Spitzer NC, et al. Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J Neurosci 1996;16:6126-33.
29. Bernardi P, Basso E, Colonna R, et al. Perspectives on the mitochondrial permeability transition. Biochim Biophys Acta 1998;1365:200-6.
30. Griffiths E, Halesetrap AP. Further evidence that cyclosporine A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase: implication for the immuno-suppressive and toxic effects of cyclosporine. Biochem J 1991;274:611-4.
31. Bernardi P, Vassanelli S, Veronese P, et al. Modulation of the mitochondrial permeability transition pore: effects of protons and divalent cations. J Biol Chem 1982;267:2934-9.
32. Duchen M, McGuinness O, Brown L, et al. On the involvement of a cyclosporin A sensitive mitochondrial pore in myocardial reperfusion injury. Cardiovasc Res 1993;27:1790-4.
33. Murphy AN, Bredesen DE, Cortopassi G, et al. Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. Proc Natl Acad Sci U S A 1996;93:9893-8.
34. Schauwecker PE, Steward O. Genetic determinants of susceptibility to excitotoxic cell death: implications for gene targeting approaches. Proc Natl Acad Sci U S A 1997;94:4103-8.
35. Racine RJ. Modification of seizure activity by electrical stimulation, II: motor seizure. Electroencephalogr Clin Neurophysiol 1972;32:281-94.
36. Nadler JV, Evenson DA. Use of excitatory amino acids to make axon-sparing lesions of the hypothalamus. Methods Enzymol 1983;103:393-400.
37. Schwob JE, Fuller T, Price JL, et al. Widespread patterns of neuronal damage following systemic of intracerebral injections of kainic acid: a histological study. Neuroscience 1980;5:991-1014.
38. Schauwecker PE, Ramirez JJ, Steward O. Genetic dissection of the signals that induce synaptic reorganization. Exp Neurol 2000;161:139-52.
39. Sidman RL, Angevine JB, Taber Pierce E. Atlas of the mouse brain and spinal cord. Cambridge: Harvard University Press, 1971.
40. Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coordinates. New York: Academic Press, 1997.
41. Adams DH, Ponsford S, Gunson B, et al. Neurological complications following transplantation. Lancet 1987;1:949-51.
42. Famiglio L, Racusen L, Fivush B, et al. Central nervous system toxicity of cyclosporine in a rat model. Transplantation 1989;48:316-21.
43. Li PA, Uchino H, Elmer E, et al. Amelioration by cyclosporine A of brain damage following 5 or 10 min of ischemia in rats subjected to preischemic hyperglycemia. Brain Res 1997;753:133-40.
44. Racusen LC, McCrindle BW. Christenson M. et al. Cyclosporine lowers seizure threshold in an experimental model of electroshockinduced seizures in Munich-Wistar rats. Life Sci 1990;46:1021-6.
45. Wong M, Yamada KA. Cyclosporine induces epileptiform activity in an in vitro seizure model. Epilepsia 2000;41:271-6.
46. Wszolek ZK, Steg RE. Seizures after orthotopic liver transplantation. Seizure 1997;6:31-9.
47. Schauwecker PE. Seizure-induced neuronal death is associated with induction of c-Jun N-terminal kinase and is dependent on genetic background. Brain Res 2000;884:116-28.
48. Nadler JV, Cuthbertson GJ. Kainic acid neurotoxicity toward hippocampal formation: dependence on specific excitatory pathways. Brain Res 1980;195:47-56.
49. Nadler JV, Perry BW, Gentry C, et al. Loss and reacquisition of hippocampal synapses after selective destruction of CA3-CA4 afferents with kainic acid. Brain Res 1980;191:387-403.
50. Serkova N, Litt L, James TL, et al. Evaluation of individual and combined neurotoxicity of the immunosuppressants cyclosporine and sirolimus by in vitro multinuclear NMR spectroscopy. J Pharm Exp Ther 1999;289:800-6.
51. 2+ loads. J Neurophysiol 1994;72:2563-9.
52. Coyle JT, Puttfarcken PS. Oxidative stress, glutamate and neurodegenerative disorders. Science 1993;262:689-95.
53. Duchen MR. Contributions of mitochondria to animal physiology: from homeostatic sensor to calcium signaling and cell death., J Physiol 1999;516:1-17.
54. Sullivan PG, Thompson M, Scheff SW. Continuous infusion of cyclosporin A post injury significantly ameliorates cortical damage following traumatic brain injury. Exp Neurol 2000;161:631-7.
55. Leventhal L, Sortwell CE, Hanburg R, et al. Cyclosporin A protects striatal neurons in vitro and in vivo from 3-nitropropionic acid toxicity. J Comp Neurol 2000;425:471-8.
56. Matsuura K, Kabuto H, Makino H, et al. Cyclosporin A attenuates degeneration of dopaminergic neurons induced by 6-hydroxydopamine in the mouse brain. Brain Res 1996;733:101-4.
57. Galat A, Metcalfe SM. Peptidylproline cis/trans isomerases. Prog Biophys Mol Biol 1995;63:67-118.
58. 2+-induced large-amplitude swelling of liver and heart mitochondria by cyclosporin is probably caused by the inhibitor binding to mitochondrial-matrix peptidyl-prolyl cis-trans isomerase and preventing it interacting with the adenine nucleotide translocase. Biochem J 1990;268:153-60.
59. 2+release to cyclosporine A and related compounds. Biochem Pharmacol 1993;45:641-6.
60. Liu D, Thangnipon W, McAdoo DJ. Excitatory amino acids rise to toxic levels upon impact injury to the spinal cord. Brain Res 1991;547:344-8.
61. Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991;251:283-7.
62. Butcher SP, Henshall DC, Teramura Y, et al. Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism. J Neurosci 1997;17:6939-46.
63. Kuroda S, Janelidze S, Siesjö BK. The immunosuppressants cyclosporin A and FK506 equally ameliorate brain damage due to 30-min middle cerebral artery occlusion in hyperglycemic rats. Brain Res 1999;835:148-53.
64. Moriwaki A, Lu Y-F, Tomizawa K, et al. An immunosuppressant, FK506, protects against neuronal dysfunction and death but has no effect on electrographic and behavioral activities induced by systemic kainate. Neuroscience 1998;86:855-65.
65. Gundimeda U, Chen ZH, Gopalakrishna R. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. J Biol Chem 1996;271:13504-14.
66. Buckman JF, Reynolds IJ. Spontaneous changes in mitochondrial membrane potential in cultured neurons. J Neurosci 2001;21:5054-65.
67. Shuttleworth CW, Connor JA. Strain-dependent differences in calcium signaling predict excitotoxicity in murine hippocampal neurons. J Neurosci 2001;21:4225-36.